NCT00543647已完成1 期
A Double-blind, Cross-over, Placebo-controlled Study Evaluating the Effect of Fenofibrate 160 mg Tablets on Glomerular Filtration Rate and Other Renal Function Test in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Glomerular filtration rate (GFR) assessed by the measure of inulin clearance
研究概览
简要总结
The purpose of this study was to test the effect of fenofibrate treatment on glomerular filtration rate (GFR), kidney hemodynamics and tubular function in middle-aged subjects with normal kidney function to further investigate the increase in creatinine levels observed in fenofibrate-treated subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female
- •Age: 30-60 years old
- •Subjects with normal renal function as documented by: Plasma creatinine < 130 µmol/L, AND Cockcroft & Gault creatinine clearance (Co Cr CL) >80 ml/min
- •Certified as normal by a comprehensive medical assessment and laboratory investigations the results of which are within the normal range /or clinically acceptable for the present subjects and who have a negative urinary screen for drugs of abuse.
- •Written informed consent
排除标准
- •Body Mass Index (BMI) ≥ 30 kg/m² or <18 kg/m².
- •Pregnant, breast-feeding, or woman with child bearing potential without a reliable method of contraception.
- •Having received an investigational drug in the last 90 days before date of inclusion.
- •With known hypersensitivity to fibrates.
- •Unable or unwilling to comply with the protocol, or likely to leave the study before its completion.
- •Who would undertake important change in physical exercise or vigorous sport competitions during the study period.
- •Drug therapies are not permitted during the study, except contraceptive pill when applicable, with the exception of occasional use of paracetamol.
- •Any administration of treatment, which could bring about induction or inhibition of hepatic microsomal enzymes within 3 months of the study start.
- •Diabetes mellitus, Heart diseases, Kidney diseases, hypertension, asthma, Liver diseases, Chronic pancreatitis, or identified risk or known history of acute pancreatitis, Known cholelithiasis without cholecystectomy, ASAT and/or ALAT > 1.3 times ULN, Gastric or peptic ulcer or intestinal diseases, Musculoskeletal diseases or increased CK > 1.0 times ULN, History of neoplasm, Mental illness, Regular user of sedatives, hypnotics, tranquillisers or any other addictive agents or who are known to be prone to alcohol abuse (i.e. history or evidence of acute abuse), or alcohol intake >14 units per week (unit = ½ pint of beer, 1 glass of wine, 2,5 cl standard spirits), or heavy smokers (>10 cigarettes/day), or excessive drinker of tea, coffee and/or beverages containing caffeine (>8 cups/day), Blood donor with recent donation (in the three months preceding the initiation of the study) or would make blood donations during the study, Blood transfusion or administration of blood-derived products, in the year preceding the study.
研究组 & 干预措施
1
Experimental
干预措施: Fenofibrate 160 mg tablet (Drug)
2
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Glomerular filtration rate (GFR) assessed by the measure of inulin clearance
时间窗: After two periods of 6 weeks treatment (fenofibrate and placebo in cross-over) separated by a 6wks wash out
次要结局
- Tubular function: creatinine clearance, albuminuria, urine N-acetyl Beta D glucosaminidase and Retinol Binding Protein, sodium clearance and sodium fractional excretion(before and after each treatment period)
- GFR evaluated by raw values of plasma creatinine and cystatin C levels(before and after each treatment period)
- Renal haemodynamics evaluated by raw values of renal plasma and blood flows(before and after each treatment period)
- Other functions : blood and urine urea, total proteins, albumin, uric acid, Na+, K+, blood fasting glucose, urinary creatinine, erythrocytes, leukocytes, casts and Calculated osmolarity, free water and urinary urate(before and after each treatment period)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT01843790La Jolla Pharmaceutical Company120
已完成
2 期
A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 DiabetesPatients With Type 2 DiabetesNCT00703482Solvay Pharmaceuticals278
终止
1 期
A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry DiseaseFabry DiseaseNCT01839526Genzyme, a Sanofi Company39
已完成
2 期
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.Patients With Metabolic SyndromeNCT00703755Solvay Pharmaceuticals2,288
撤回
1 期
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033ObesityNCT00376285Pfizer